XIX International AIDS Conference
 

• Cobicistat versus ritonavir as pharmacoenhancers in combination with atazanavir plus tenofovir disoproxil fumarate/emtricitabine: phase 3 randomized, double blind, active-controlled trial, week 48 results
  J. Gallant, E. Koenig, J. Andrade-Villanueva, et al
  Abstract
• Analysis of efficacy by baseline viral load: phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (quad) versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment-naïve HIV-1-positive subjects: week 48 results
  E. DeJesus, J. Rockstroh, K. Henry, et al
• Analysis of efficacy by baseline HIV RNA: week 48 results from a phase 3 study of elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to efavirenz/emtricitabine/tenofovir DF in treatment-naïve HIV-1-positive subjects
  P. Sax, E. De Jesus, A. Mills,, et al
• The clinical and economic impact of a generic first-line antiretroviral regimen in the U.S.
  R.P. Walensky , P.E. Sax , Y.M. Nakamura , et al